vs
Evercore Inc.（EVR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Evercore Inc.的季度营收约是Revvity的1.8倍（$1.4B vs $772.1M），Evercore Inc.净利率更高（23.0% vs 12.7%，领先10.3%），Evercore Inc.同比增速更快（100.3% vs 5.9%），过去两年Evercore Inc.的营收复合增速更高（42.2% vs 9.0%）
Evercore Inc.（前称Evercore Partners）是1995年由罗杰·奥尔特曼、大卫·奥芬森德、奥斯汀·博伊特纳联合创立的全球独立投资银行咨询机构。成立至今，公司已为总规模超4.7万亿美元的并购、重组交易提供专业咨询服务，在全球投行业务领域拥有较高声誉。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
EVR vs RVTY — 直观对比
营收规模更大
EVR
是对方的1.8倍
$772.1M
营收增速更快
EVR
高出94.4%
5.9%
净利率更高
EVR
高出10.3%
12.7%
两年增速更快
EVR
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $772.1M |
| 净利润 | $322.7M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 23.0% | 12.7% |
| 营收同比 | 100.3% | 5.9% |
| 净利润同比 | 106.1% | 3.9% |
| 每股收益（稀释后） | $7.20 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EVRRVTY
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.0B | $698.9M | ||
| Q2 25 | $838.0M | $720.3M | ||
| Q1 25 | $699.0M | $664.8M | ||
| Q4 24 | $979.5M | $729.4M | ||
| Q3 24 | $738.4M | $684.0M | ||
| Q2 24 | $693.4M | $691.7M |
净利润EVRRVTY
| Q1 26 | $322.7M | — | ||
| Q4 25 | $204.0M | $98.4M | ||
| Q3 25 | $144.6M | $46.7M | ||
| Q2 25 | $97.2M | $53.9M | ||
| Q1 25 | $146.2M | $42.2M | ||
| Q4 24 | $140.4M | $94.6M | ||
| Q3 24 | $78.4M | $94.4M | ||
| Q2 24 | $73.8M | $55.4M |
毛利率EVRRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率EVRRVTY
| Q1 26 | — | — | ||
| Q4 25 | 24.2% | 14.5% | ||
| Q3 25 | 20.8% | 11.7% | ||
| Q2 25 | 18.0% | 12.6% | ||
| Q1 25 | 16.0% | 10.9% | ||
| Q4 24 | 21.8% | 16.3% | ||
| Q3 24 | 16.7% | 14.3% | ||
| Q2 24 | 15.9% | 12.4% |
净利率EVRRVTY
| Q1 26 | 23.0% | — | ||
| Q4 25 | 15.7% | 12.7% | ||
| Q3 25 | 13.8% | 6.7% | ||
| Q2 25 | 11.6% | 7.5% | ||
| Q1 25 | 20.9% | 6.4% | ||
| Q4 24 | 14.3% | 13.0% | ||
| Q3 24 | 10.6% | 13.8% | ||
| Q2 24 | 10.6% | 8.0% |
每股收益（稀释后）EVRRVTY
| Q1 26 | $7.20 | — | ||
| Q4 25 | $4.80 | $0.86 | ||
| Q3 25 | $3.41 | $0.40 | ||
| Q2 25 | $2.36 | $0.46 | ||
| Q1 25 | $3.48 | $0.35 | ||
| Q4 24 | $3.32 | $0.77 | ||
| Q3 24 | $1.86 | $0.77 | ||
| Q2 24 | $1.81 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $7.3B |
| 总资产 | — | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EVRRVTY
| Q1 26 | — | — | ||
| Q4 25 | $3.0B | $919.9M | ||
| Q3 25 | $2.4B | $931.4M | ||
| Q2 25 | $1.7B | $991.8M | ||
| Q1 25 | $1.4B | $1.1B | ||
| Q4 24 | $2.4B | $1.2B | ||
| Q3 24 | $1.8B | $1.2B | ||
| Q2 24 | $1.7B | $2.0B |
股东权益EVRRVTY
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $7.3B | ||
| Q3 25 | $1.8B | $7.4B | ||
| Q2 25 | $1.7B | $7.6B | ||
| Q1 25 | $1.5B | $7.6B | ||
| Q4 24 | $1.7B | $7.7B | ||
| Q3 24 | $1.6B | $7.9B | ||
| Q2 24 | $1.5B | $7.9B |
总资产EVRRVTY
| Q1 26 | — | — | ||
| Q4 25 | $5.4B | $12.2B | ||
| Q3 25 | $4.4B | $12.1B | ||
| Q2 25 | $3.7B | $12.4B | ||
| Q1 25 | $3.3B | $12.4B | ||
| Q4 24 | $4.2B | $12.4B | ||
| Q3 24 | $3.6B | $12.8B | ||
| Q2 24 | $3.3B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流EVRRVTY
| Q1 26 | — | — | ||
| Q4 25 | $807.5M | $182.0M | ||
| Q3 25 | $560.9M | $138.5M | ||
| Q2 25 | $437.7M | $134.3M | ||
| Q1 25 | $-549.7M | $128.2M | ||
| Q4 24 | $686.4M | $174.2M | ||
| Q3 24 | $234.5M | $147.9M | ||
| Q2 24 | $348.5M | $158.6M |
自由现金流EVRRVTY
| Q1 26 | — | — | ||
| Q4 25 | $798.6M | $161.8M | ||
| Q3 25 | $541.5M | $120.0M | ||
| Q2 25 | $411.7M | $115.5M | ||
| Q1 25 | $-569.3M | $112.2M | ||
| Q4 24 | $673.1M | $149.8M | ||
| Q3 24 | $226.6M | $125.6M | ||
| Q2 24 | $340.7M | $136.6M |
自由现金流率EVRRVTY
| Q1 26 | — | — | ||
| Q4 25 | 61.6% | 21.0% | ||
| Q3 25 | 51.8% | 17.2% | ||
| Q2 25 | 49.1% | 16.0% | ||
| Q1 25 | -81.4% | 16.9% | ||
| Q4 24 | 68.7% | 20.5% | ||
| Q3 24 | 30.7% | 18.4% | ||
| Q2 24 | 49.1% | 19.7% |
资本支出强度EVRRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.7% | 2.6% | ||
| Q3 25 | 1.9% | 2.6% | ||
| Q2 25 | 3.1% | 2.6% | ||
| Q1 25 | 2.8% | 2.4% | ||
| Q4 24 | 1.4% | 3.4% | ||
| Q3 24 | 1.1% | 3.3% | ||
| Q2 24 | 1.1% | 3.2% |
现金转化率EVRRVTY
| Q1 26 | — | — | ||
| Q4 25 | 3.96× | 1.85× | ||
| Q3 25 | 3.88× | 2.97× | ||
| Q2 25 | 4.50× | 2.49× | ||
| Q1 25 | -3.76× | 3.03× | ||
| Q4 24 | 4.89× | 1.84× | ||
| Q3 24 | 2.99× | 1.57× | ||
| Q2 24 | 4.72× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EVR
| Advisory Fees (1) | $1.2B | 89% |
| Commissions and Related Revenue | $62.7M | 4% |
| Underwriting Fees | $55.1M | 4% |
| Asset Management and Administration Fees (2) | $23.7M | 2% |
| Other Revenue, net | $15.4M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
